Polymer Delivery of Camptothecin against 9L Gliosarcoma: Release, Distribution, and Efficacy

[1]  W. Saltzman,et al.  Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. , 1998, Cancer research.

[2]  H Kalimo,et al.  Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. , 1997, Neurosurgery.

[3]  S. Piantadosi,et al.  Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors , 1997, Cancer Chemotherapy and Pharmacology.

[4]  D. Brat,et al.  Interstitial delivery of carboplatin via biodegradable Polymers is effective against experimental glioma in the rat , 1996, Cancer Chemotherapy and Pharmacology.

[5]  H. Brem,et al.  Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model , 1995, International journal of cancer.

[6]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[7]  M. Bjornsti,et al.  A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons (*) , 1995, The Journal of Biological Chemistry.

[8]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.

[9]  T. Burke,et al.  Differential interactions of camptothecin lactone and carboxylate forms with human blood components. , 1994, Biochemistry.

[10]  T. Tamaya,et al.  Semi‐quantitative Analysis of DNA Topoisomerase‐I mRNA Level Using Reverse Transcription‐Polymerase Chain Reaction in Cancer Cell Lines: Its Relation to Cytotoxicity against Camptothecin Derivative , 1994, Japanese journal of cancer research : Gann.

[11]  P. Burger,et al.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. , 1994, Cancer research.

[12]  M. Potměšil,et al.  Camptothecins: from bench research to hospital wards. , 1994, Cancer research.

[13]  R. Tamargo,et al.  Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. , 1993, Cancer research.

[14]  K. Judy,et al.  Controlled release of 4-hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer , 1992 .

[15]  V. Stella,et al.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.

[16]  R. Tamargo,et al.  The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. , 1992, Journal of neurosurgery.

[17]  A. Friedman,et al.  Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. , 1991, Journal of neurosurgery.

[18]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[19]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[20]  R. Hertzberg,et al.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. , 1989, Biochemistry.

[21]  R. Tamargo,et al.  Brain biocompatibility of a biodegradable, controlled-release polymer in rats. , 1989, Journal of biomedical materials research.

[22]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[23]  R. Tamargo,et al.  Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. , 1989, Selective cancer therapeutics.

[24]  F. Traganos,et al.  Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. , 1988, Cancer research.

[25]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[26]  Robert Langer,et al.  Polyanhydrides. I: Preparation of high molecular weight polyanhydrides , 1987 .

[27]  M. Gellert,et al.  Mechanistic aspects of DNA topoisomerases. , 1986, Advances in protein chemistry.

[28]  R Langer,et al.  Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. , 1986, Journal of biomedical materials research.

[29]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[30]  R Langer,et al.  Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. , 1985, Journal of biomedical materials research.

[31]  M. Wani,et al.  Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. , 1980, Journal of medicinal chemistry.

[32]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[33]  D. Kessel,et al.  Camptothecin effects on DNA synthesis in murine leukemia cells. , 1972, Biochimica et biophysica acta.

[34]  Gottlieb Ja,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972 .

[35]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[36]  J A Gottlieb,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972, Cancer chemotherapy reports.

[37]  M. Horwitz,et al.  Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. , 1971, Biochemical and biophysical research communications.

[38]  D. Kessel,et al.  Effects of camptothecin on RNA synthesis in leukemia L1210 cells. , 1971, Biochimica et biophysica acta.

[39]  R. Adamson,et al.  Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. , 1971, Journal of the National Cancer Institute.

[40]  A. Guarino,et al.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.

[41]  A. Goldin,et al.  Studies on therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinosarcoma. , 1968, Cancer chemotherapy reports.

[42]  J. Venditti,et al.  Studies on oncolytic agents from natural sources. Correlations of activity against animal tumors and clinical effectiveness. , 1967 .

[43]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .